Design and synthesis of a series of 6-substituted-2- pyridinylmethylamine derivatives as novel, high-affinity, selective agonists at 5-HT(1A) receptors

Journal of Medicinal Chemistry

Volumn 41, Issue 25, 1998, Pages 5070-5083

  Vacher, Bernard ^a   Bonnaud, Bernard ^a   Funes, Philippe ^a   Jubault, Nathalie ^a   Koek, Wouter ^a   Assié, Marie Bernadette ^a   Cosi, Cristina ^a  

^a INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

(3,4 DICHLOROPHENYL) [4 [(6 AZETIDINOPYRIDIN 2 YLMETHYLAMINO)METHYL]PIPERIDIN 1 YL]METHANONE; (3,4 DICHLOROPHENYL) [4 [(6 OXAZOL 5 YLPYRIDIN 2 YLMETHYLAMINO)METHYL]PIPERIDIN 1 YL]METHANONE; SEROTONIN 1A AGONIST; UNCLASSIFIED DRUG;

ARTICLE; DRUG CONFORMATION; DRUG DESIGN; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; HELA CELL; RECEPTOR AFFINITY; STRUCTURE ACTIVITY RELATION; THERMODYNAMICS;

8-HYDROXY-2-(DI-N-PROPYLAMINO)TETRALIN; ANIMALS; ANTIDEPRESSIVE AGENTS; AZETIDINES; CELL LINE; CYCLIC AMP; DRUG DESIGN; FORSKOLIN; HELA CELLS; HUMANS; METHYLAMINES; MICE; OXAZOLES; PYRIDINES; RECEPTORS, ADRENERGIC, ALPHA-1; RECEPTORS, DOPAMINE D2; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT1; SEROTONIN AGONISTS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0032480915     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9804329     Document Type: Article

References (61)

1. Hoyer, D.; Clarke, D. E.; Fozard, J. R.; Hartig, P. R.; Martin, G. R.; Mylecharane, E. J.; Saxena, P. R.; Humphrey, P. A. Pharmacol. Rev. 1994, 46, 157-203.
2. Peroutka, S. J. CNS Drugs 1995, 4 (Suppl. 1), 18-28.
3. Barradell, L. B.; Fitton, A. CNS Drugs 1996, 5, 147-153. Pecknold, J. C. CNS Drugs 1994, 2, 234-251. Deakin, J. F. W. J. Psychopharmacol. 1993, 7, 283-289. Stahl, S. M. J. Clin. Psychiatry 1997, 58 (Suppl. 8), 20-26.
4. Barradell, L. B.; Fitton, A. CNS Drugs 1996, 5, 147-153. Pecknold, J. C. CNS Drugs 1994, 2, 234-251. Deakin, J. F. W. J. Psychopharmacol. 1993, 7, 283-289. Stahl, S. M. J. Clin. Psychiatry 1997, 58 (Suppl. 8), 20-26.
5. Barradell, L. B.; Fitton, A. CNS Drugs 1996, 5, 147-153. Pecknold, J. C. CNS Drugs 1994, 2, 234-251. Deakin, J. F. W. J. Psychopharmacol. 1993, 7, 283-289. Stahl, S. M. J. Clin. Psychiatry 1997, 58 (Suppl. 8), 20-26.
6. Barradell, L. B.; Fitton, A. CNS Drugs 1996, 5, 147-153. Pecknold, J. C. CNS Drugs 1994, 2, 234-251. Deakin, J. F. W. J. Psychopharmacol. 1993, 7, 283-289. Stahl, S. M. J. Clin. Psychiatry 1997, 58 (Suppl. 8), 20-26.
7. Blier, P.; Bergeron, R. Int. Clin. Psychopharmacol. 1997, 12 (Suppl. 3), 21-28.
8. Blier, P.; Bergeron, R.; De Montigny, C. Neuropsychopharmacology 1997, 16, 333-338. Matsuda, T.; Somboonthum, P.; Suzuki, M.; Asano, S.; Baba, A. Eur. J. Pharmacol. 1995, 280, 235-238. Glennon, R. A.; Malgorzata, D. Serotonin 1997, 2, 351-372.
9. Blier, P.; Bergeron, R.; De Montigny, C. Neuropsychopharmacology 1997, 16, 333-338. Matsuda, T.; Somboonthum, P.; Suzuki, M.; Asano, S.; Baba, A. Eur. J. Pharmacol. 1995, 280, 235-238. Glennon, R. A.; Malgorzata, D. Serotonin 1997, 2, 351-372.
10. Blier, P.; Bergeron, R.; De Montigny, C. Neuropsychopharmacology 1997, 16, 333-338. Matsuda, T.; Somboonthum, P.; Suzuki, M.; Asano, S.; Baba, A. Eur. J. Pharmacol. 1995, 280, 235-238. Glennon, R. A.; Malgorzata, D. Serotonin 1997, 2, 351-372.
11. Glennon, R. A. Drug Dev. Res. 1992, 26, 251-274. Shutske, G. M. Exp. Opin. Ther. Patents 1994, 4, 1233-1241. Schechter, L. E.; Kelly, M. G. Serotonin 1997, 2, 299-309. Fletcher, A.; Cliffe, I. A.; Dourish, C. T. Trends Pharmacol. Sci. 1993, 14, 441-448.
12. Glennon, R. A. Drug Dev. Res. 1992, 26, 251-274. Shutske, G. M. Exp. Opin. Ther. Patents 1994, 4, 1233-1241. Schechter, L. E.; Kelly, M. G. Serotonin 1997, 2, 299-309. Fletcher, A.; Cliffe, I. A.; Dourish, C. T. Trends Pharmacol. Sci. 1993, 14, 441-448.
13. Glennon, R. A. Drug Dev. Res. 1992, 26, 251-274. Shutske, G. M. Exp. Opin. Ther. Patents 1994, 4, 1233-1241. Schechter, L. E.; Kelly, M. G. Serotonin 1997, 2, 299-309. Fletcher, A.; Cliffe, I. A.; Dourish, C. T. Trends Pharmacol. Sci. 1993, 14, 441-448.
14. Glennon, R. A. Drug Dev. Res. 1992, 26, 251-274. Shutske, G. M. Exp. Opin. Ther. Patents 1994, 4, 1233-1241. Schechter, L. E.; Kelly, M. G. Serotonin 1997, 2, 299-309. Fletcher, A.; Cliffe, I. A.; Dourish, C. T. Trends Pharmacol. Sci. 1993, 14, 441-448.
15. Crabb, T. A.; Fallah, A. Magn. Reson. Chem. 1990, 28, 426-430.
16. Comins, D. L.; Killpack, M. O. J. Org. Chem. 1990, 55, 69-73.
17. Aliprantis, A. O.; Canary, J. W. J. Am. Chem. Soc. 1994, 116, 6985-6986.
18. Zamboni, R. Pyridine-substituted Benzyl Alcohols as Leukotriene Antagonists. WO 93/21158, 1993.
19. Gale, D. J.; Wilshire, J. F. K. Aust. J. Chem. 1975, 28, 2447-2458.
20. Artico, M.; Corelli, F.; Massa, S.; Stefancich, G.; Avigliano, L.; Befani, O.; Marcozzi, G.; Sabatini, S.; Mondovi, B. J. Med. Chem. 1988, 37, 802-806.
21. Bredereck, H.; Simchem, G.; Wahl, R. Chem. Ber. 1968, 101, 4048-4056.
22. Vetelino, M. G.; Coe, J. W. Tetrahedron Lett. 1994, 35, 219-222.
23. Hamana, M.; Yamazaki, M. Chem. Pharm. Bull. (Tokyo) 1960, 8, 574-578.
24. Sieburth, S.; Chen, J. L. J. Am. Chem. Soc. 1991, 113, 8163-8164.
25. Kan, T.; Hashimoto, M.; Yanagiya, M.; Shirahama, H. Tetrahedron Lett. 1988, 29, 5417-5418.
26. Eichenger, K.; Berbalk, H.; Kronberger, H. Synthesis 1982, 12, 1094-1095.
27. Hughey, J. L.; Knapp, S.; Schugar, V. Synthesis 1980, 6, 489-490.
28. Evans, D. L.; Minster, D. K.; Jordis, V.; Hecht, S. M.; Mazzu, A. L. J. Org. Chem. 1979, 44, 497-501.
29. Amoroso, A. J.; Cargill Thomson, A. M.; Jeffery, J. C.; Jones, P. L.; McCleverty, J. A.; Ward, M. D. J. Chem. Soc., Chem. Commun. 1994, 2751-2752.
30. Falk, H.; Suste, A. Monatsh. Chem. 1993, 124, 881-891.
31. VanLeussen, A. M.; Hoogenboom, B. E.; Siderius, H. Tetrahedron Lett. 1972, 23, 2369-2372.
32. Fargin, A.; Raymond, J. R.; Regan, J. W.; Cotecchia, S.; Lefkowitz, R. J. J. Biol. Chem. 1989, 264, 14848-14852.
33. Bikker, J. A.; Trumpp-Kallmeyer, S.; Humblet, C. J. Med. Chem. 1998, 47, 2911-2927.
34. Wess, J. Faseb J. 1997, 11, 346-354.
35. Osman, R.; Topiol, S.; Rubenstein, L.; Weintein, H. Mol. Pharmacol. 1987, 32, 699-705. Pardo, L.; Weinstein, H. Int. J. Quant. Chem. 1997, 63, 767-780.
36. Osman, R.; Topiol, S.; Rubenstein, L.; Weintein, H. Mol. Pharmacol. 1987, 32, 699-705. Pardo, L.; Weinstein, H. Int. J. Quant. Chem. 1997, 63, 767-780.
37. Burley, S. K.; Petsko, G. A. Adv. Protein Chem. 1988, 39, 125-189. Dalpiaz, A.; Borea, P. A.; Gessi, J.; Gilli, G. Eur. J. Pharmacol. 1996, 372, 107-114.
38. Burley, S. K.; Petsko, G. A. Adv. Protein Chem. 1988, 39, 125-189. Dalpiaz, A.; Borea, P. A.; Gessi, J.; Gilli, G. Eur. J. Pharmacol. 1996, 372, 107-114.
39. Chilmonczyk, Z. J. Pharm. Pharmacol. 1995, 47, 791-801 and references therein.
40. Bigg, D.; Castan, F.; Koek, W.; Bonnaud, B. Novel Heterocyclic Aminomethyl-4 Piperidine Derivatives, their Preparation and Application in Therapy. WO 94/18193-A1, 1994. Bonnaud, B.; Castan, F.; Bigg, D.; Koek, W. Nouveaux derives de la phenoxy-2 éthylamine, leur preparation et leur application en thérapeutique. FR 2702211, 1993.
41. Bigg, D.; Castan, F.; Koek, W.; Bonnaud, B. Novel Heterocyclic Aminomethyl-4 Piperidine Derivatives, their Preparation and Application in Therapy. WO 94/18193-A1, 1994. Bonnaud, B.; Castan, F.; Bigg, D.; Koek, W. Nouveaux derives de la phenoxy-2 éthylamine, leur preparation et leur application en thérapeutique. FR 2702211, 1993.
42. Mokrosz, J. L.; Deren-Wezolek, A.; Tatarcznska, E.; Duszynska, B.; Bojarski, A. J.; Mokrosz, M. J.; Chojnacka-Wojcik, E. J. Med. Chem. 1996, 39, 1125-1129. George, P.; Sevrin, M.; Maloizel, C.; Tixidre, A.; Froissant, J. 4-Piperidinyl methyl tetrahydro isoquinolines having Selective Affinity for Serotoninergic Receptors. EP 0351255, 1989. George, P.; Sevrin, M.; Mangane, M.; Merly, J.-P.; Bigg, D. Piperidinyl Isoindoles and Benzazepines having Selecte Affinity for Serotoninergic Receptors. EP 0351283, 1989.
43. Mokrosz, J. L.; Deren-Wezolek, A.; Tatarcznska, E.; Duszynska, B.; Bojarski, A. J.; Mokrosz, M. J.; Chojnacka-Wojcik, E. J. Med. Chem. 1996, 39, 1125-1129. George, P.; Sevrin, M.; Maloizel, C.; Tixidre, A.; Froissant, J. 4-Piperidinyl methyl tetrahydro isoquinolines having Selective Affinity for Serotoninergic Receptors. EP 0351255, 1989. George, P.; Sevrin, M.; Mangane, M.; Merly, J.-P.; Bigg, D. Piperidinyl Isoindoles and Benzazepines having Selecte Affinity for Serotoninergic Receptors. EP 0351283, 1989.
44. Mokrosz, J. L.; Deren-Wezolek, A.; Tatarcznska, E.; Duszynska, B.; Bojarski, A. J.; Mokrosz, M. J.; Chojnacka-Wojcik, E. J. Med. Chem. 1996, 39, 1125-1129. George, P.; Sevrin, M.; Maloizel, C.; Tixidre, A.; Froissant, J. 4-Piperidinyl methyl tetrahydro isoquinolines having Selective Affinity for Serotoninergic Receptors. EP 0351255, 1989. George, P.; Sevrin, M.; Mangane, M.; Merly, J.-P.; Bigg, D. Piperidinyl Isoindoles and Benzazepines having Selecte Affinity for Serotoninergic Receptors. EP 0351283, 1989.
45. Chidiac, P. Trends Pharmacol. Sci. 1995, 16, 83-84. Kenakin, T. Trends Pharmacol. Sci. 1995, 16, 84-85.
46. Chidiac, P. Trends Pharmacol. Sci. 1995, 16, 83-84. Kenakin, T. Trends Pharmacol. Sci. 1995, 16, 84-85.
47. Leff, P. Trends Pharmacol. Sci. 1995, 16, 89-87.
48. A similar trend was observed with trans-2-aryl-N,N-dipropyl-cyclopropylamine derivatives: Vallgarda, J.; Appelberg, U.; Arvidsson, L. E.; Hjorth, S.; Svensson, B. E.; Hacksell, U. J. Med. Chem. 1996, 39, 1485-1493. Langlois, M.; Gaudy, S.; Bremont, S.; Bremont, B. BioMed. Chem. Lett. 1993, 3, 2035-2038.
49. A similar trend was observed with trans-2-aryl-N,N-dipropyl-cyclopropylamine derivatives: Vallgarda, J.; Appelberg, U.; Arvidsson, L. E.; Hjorth, S.; Svensson, B. E.; Hacksell, U. J. Med. Chem. 1996, 39, 1485-1493. Langlois, M.; Gaudy, S.; Bremont, S.; Bremont, B. BioMed. Chem. Lett. 1993, 3, 2035-2038.
50. Van Wijngaarden, I.; Tulp, M. Th. M.; Soudïjn, W. Eur. J. Pharmacol. 1990, 188, 301-312. Hamon, M.; Fattaccini, C. M.; Adrien, J.; Gallissot, M. C.; Martin, P.; Gozlan, H. J. Pharmacol. Exp. Ther. 1988, 246, 745-752.
51. Van Wijngaarden, I.; Tulp, M. Th. M.; Soudïjn, W. Eur. J. Pharmacol. 1990, 188, 301-312. Hamon, M.; Fattaccini, C. M.; Adrien, J.; Gallissot, M. C.; Martin, P.; Gozlan, H. J. Pharmacol. Exp. Ther. 1988, 246, 745-752.
52. 1A agonist activity: Caccia, S. Bull. Chim. Farm. 1990, 129, 183-189. Berlin, I.; Chalon, S.; Payan, C.; Schöllnhammer, G.; Cesselin, F.; Varoquaux, O.; Puech, A. J. Br. J. Clin. Pharmacol. 1995, 39, 243-249.
53. 1A agonist activity: Caccia, S. Bull. Chim. Farm. 1990, 129, 183-189. Berlin, I.; Chalon, S.; Payan, C.; Schöllnhammer, G.; Cesselin, F.; Varoquaux, O.; Puech, A. J. Br. J. Clin. Pharmacol. 1995, 39, 243-249.
54. 1A agonist activity: Caccia, S. Bull. Chim. Farm. 1990, 129, 183-189. Berlin, I.; Chalon, S.; Payan, C.; Schöllnhammer, G.; Cesselin, F.; Varoquaux, O.; Puech, A. J. Br. J. Clin. Pharmacol. 1995, 39, 243-249.
55. 3I/HNa; thus we assumed that the hydrogen atom is preferentially located on N-1.
56. Martina, S.; Enkelmann, V.; Wegner, G.; Schlüter, A. D. Synthesis 1991, 8, 613-615.
57. Known amines used for the preparation of compounds 75-80, 82, and 84 are respectively: dipropylamine [142-84-7]; 4-methoxyphenylethylamine [55-81-2]; 5-methoxytryptamine [608-07-1]; N-(2-aminoethyl)tricyclo[3.3.1.13,7]decane-1-carboxamide [190657-27-3];2-(4-aminobutyl)-4-methyl-2H-[1,2,4]triazine-3,5-dione. Patoiseau, J.-F.; Faure, C.; Dupont-Passelaigue, E.; Couret, F. Novel 3,5-dioxo-(2H,4H)-1,2,4-triazine derivatives, their preparation and use as drugs. WO 96/16949, 1996. 4,4-Bis(p-fluorophenyl)butylamine [64630-52-0]; N-(4-aminobutyl)-3-methylbenzamide was prepared in an analogous manner as N-(4-aminobutyl)benzamide: Zaragoza-Doerwald, F.; Von Kiedrowski, G. Synthesis 1988, 11, 917-918. [4-(Aminomethyl)piperidin-1-yl](3-chlorophenyl)methanone: Roll, W. D. Piperidinylalkylbenzamide compositions for inhibiting H2 histamine receptors. US 4310532, 1980.
58. Known amines used for the preparation of compounds 75-80, 82, and 84 are respectively: dipropylamine [142-84-7]; 4-methoxyphenylethylamine [55-81-2]; 5-methoxytryptamine [608-07-1]; N-(2-aminoethyl)tricyclo[3.3.1.13,7]decane-1-carboxamide [190657-27-3];2-(4-aminobutyl)-4-methyl-2H-[1,2,4]triazine-3,5-dione. Patoiseau, J.-F.; Faure, C.; Dupont-Passelaigue, E.; Couret, F. Novel 3,5-dioxo-(2H,4H)-1,2,4-triazine derivatives, their preparation and use as drugs. WO 96/16949, 1996. 4,4-Bis(p-fluorophenyl)butylamine [64630-52-0]; N-(4-aminobutyl)-3-methylbenzamide was prepared in an analogous manner as N-(4-aminobutyl)benzamide: Zaragoza-Doerwald, F.; Von Kiedrowski, G. Synthesis 1988, 11, 917-918. [4-(Aminomethyl)piperidin-1-yl](3-chlorophenyl)methanone: Roll, W. D. Piperidinylalkylbenzamide compositions for inhibiting H2 histamine receptors. US 4310532, 1980.
59. Known amines used for the preparation of compounds 75-80, 82, and 84 are respectively: dipropylamine [142-84-7]; 4-methoxyphenylethylamine [55-81-2]; 5-methoxytryptamine [608-07-1]; N-(2-aminoethyl)tricyclo[3.3.1.13,7]decane-1-carboxamide [190657-27-3];2-(4-aminobutyl)-4-methyl-2H-[1,2,4]triazine-3,5-dione. Patoiseau, J.-F.; Faure, C.; Dupont-Passelaigue, E.; Couret, F. Novel 3,5-dioxo-(2H,4H)-1,2,4-triazine derivatives, their preparation and use as drugs. WO 96/16949, 1996. 4,4-Bis(p-fluorophenyl)butylamine [64630-52-0]; N-(4-aminobutyl)-3-methylbenzamide was prepared in an analogous manner as N-(4-aminobutyl)benzamide: Zaragoza-Doerwald, F.; Von Kiedrowski, G. Synthesis 1988, 11, 917-918. [4-(Aminomethyl)piperidin-1-yl](3-chlorophenyl)methanone: Roll, W. D. Piperidinylalkylbenzamide compositions for inhibiting H2 histamine receptors. US 4310532, 1980.
60. Assié, M.-B.; Koek, W. Eur. J. Pharmacol. 1996, 304, 15-21.
61. Assié, M.-B.; Sleight, A. J.; Koek, W. Eur. J. Pharmacol. 1993, 237, 183-189.